Burning more money, making more money, less crowded PD-1 track, is BeiGene anxious? -News-Tianya Pharmaceutical Network


2022-09-26: [Chinese Article Link] However, in 2019, its BTK inhibitors and PD-1 drugs were expected to be marketed, and the expansion of later adaptation certificates was one of the current priorities of the State. ‘In four years, 12 adaptation certificates will be approved,’ said Wu Xiaobin, General Manager and Managing Director of


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.




Trending in China

What China Reads


Burning more money, making more money, less crowded PD-1 track, is BeiGene anxious? -News-Tianya Pharmaceutical Network


2022-09-26: [Article Link] However, in 2019, its BTK inhibitors and PD-1 drugs were expected to be marketed, and the expansion of later adaptation certificates was one of the current priorities of the State. ‘In four years, 12 adaptation certificates will be approved,’ said Wu Xiaobin, General Manager and Managing Director of

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.